High-level Aminoglycoside Resistance and Reduced Susceptibility to Vancomycin in Nosocomial Enterococci

Objectives: The objectives of the present study were to identify the species of enterococci isolated from nosocomial infections and to determine the antibiotic susceptibility pattern with reference to high-level aminoglycosides and vancomycin. Materials and Methods: Enterococci were isolated from various clinical samples collected from patients after 72 hours of hospitalization. Various species of Enterococcus were identified by standard methods. High-level aminoglycoside resistance and vancomycin susceptibility in enterococci were detected by disk-diffusion and agar-screen methods. Results: One hundred eighty enterococcal strains were isolated from various clinical samples. Various species of Enterococcus — Enterococcus fecalis 130 (72.22%), Enterococcus casseliflavus 24 (13.33%), Enterococcus fecium 17 (9.44%), Enterococcus durans 7 (3.89%) and Enterococcus dispar 2 (1.11%) — were isolated. The highest resistance to aminoglycoside was observed among E. fecium, followed by E. durans, E. fecalis and E. casseliflavus, both by disk-diffusion and agar-screen methods. The high-level aminoglycoside resistance (HLAR) was significantly (P<0.05) higher in E. fecium by agar-screen method. All enterococci showed minimum inhibitory concentration (MIC) of ≤8 μg/mL to vancomycin. Sixteen (12.31%) E. fecalis and 3 (12.5%) E. fecium strains were intermediately resistant to vancomycin (MIC= 8 μg/mL), whereas other strains were susceptible to vancomycin. Conclusion: The occurrence of high-level aminoglycoside resistance in enterococcal isolates in our setup was high. Even though none of the enterococcal strains showed resistance to vancomycin, yet reduced susceptibility to vancomycin was noticed in our study. This would require routine testing of enterococcal isolates for HLAR and vancomycin susceptibility. Agar-screen method was found to be superior to disk-diffusion method in detecting resistant strains to aminoglycosides and vancomycin.

A common regime for treatment of serious enterococcal infections is the combination of cell-wall inhibitors, such as penicillin, ampicillin or vancomycin; with aminoglycosides, such as streptomycin or gentamicin. [8] The addition of cell-wall inhibitor agent helps in the penetration of the aminoglycoside into the bacterial cytoplasm, making the intrinsically resistant organism aminoglycoside sensitive. Reduced susceptibility to vancomycin will interfere with the penetration of the aminoglycoside into the bacterial cytoplasm, thus making the synergism ineffective. The presence of HLAR in enterococci, defined as minimum inhibitory concentration of ≥2000 µg/mL of aminoglycoside for the isolate, makes the synergism of cell-wall inhibitor and aminoglycoside ineffective. [9] The main objectives of the present study were to identify the species of enterococci isolated from nosocomial infections and to determine the antibiotic susceptibility pattern with reference to high-level aminoglycosides and vancomycin.

Study population
The study population included patients of all age groups hospitalized at Government Wenlock Hospital, Government Lady Goschen Hospital, Kasturba Medical College Hospital, Attavar; and University Medical Centre, Mangalore, Karnataka, India. Infection was considered nosocomial if it developed more than 72 hours after admission to hospital. [10]

Isolation and identification
Enterococci were isolated from various clinical samples (pus, urine, blood and peritoneal aspirate).

Detection of HLAR in enterococci by disk-diffusion and agar-dilution methods
HLAR in enterococci was detected by disk-diffusion method and agar-screening method. [13] In disk-diffusion method, isolated colonies of enterococci were inoculated into peptone water to get bacterial suspension that was equivalent to McFarland 0.5 standard. Lawn culture on blood agar was done by swabbing the bacterial suspension. High-level (120 µg) gentamicin and streptomycin (300 µg) disks were placed on the agar medium. Plates were incubated at 37°C for 24 hours, and diameter of zone of inhibition was measured. Resistance was indicated by no zone; and susceptibility, by a zone of diameter ≥10 mm. Strains with inhibition zones of 7 to 9 mm were re-tested by dilution method. In agar-screen method, brain-heart infusion agar (BHIA, Hi Media, Mumbai) was supplemented with 500 µg/mL gentamicin and 2000 µg/ mL streptomycin separately. The plates were inoculated by spotting 10 µL of bacterial suspension that was equivalent to McFarland 0.5 standard prepared from growth on 24hour incubated agar plate giving a final inoculum of 10 6 cfu/ spot. The plates were incubated at 37°C for 24 hours. Presence of more than one colony or a haze of growth was read as resistance. Aminoglycoside plates which did not show bacterial growth after 24-hour incubation were incubated for additional 24 hours. The test was quality controlled using E. fecalis ATCC 29212 (susceptible) and E. fecalis ATCC 51299 (resistant).

Determination of minimum inhibitory concentration of vancomycin. [13]
Agar dilution was used to determine MIC of vancomycin to enterococci. Brain-heart infusion agar (Hi Media, Mumbai) was supplemented with different concentrations of vancomycin. The test organism was grown in broth and the turbidity matched with McFarland 0.5 standard (approximately 1.5 × 10 8 cfu/mL). Spot inoculation of the agar medium was done using 10 µL of bacterial culture. Growth control was used with each series of test. The plates were incubated at 37°C for 24 hours and examined. The minimum concentration of vancomycin which inhibited bacterial growth was considered MIC. Enterococci which had MIC ≥32 µg/mL were considered resistant; MIC of 8-16 µg/mL, as intermediately resistant; and MIC of 4 µg/ mL, as susceptible to vancomycin. [14] Statistics Statistical evaluation of the result of antibiotic sensitivity test was done using 'Z' test for proportions.

DISCUSSION
Enterococci show intrinsic low-level cross resistance to all aminoglycosides due to decreased uptake of antibiotics. [15] Therefore, there is no meaning in testing susceptibility of clinical isolates of enterococci to low-level aminoglycosides. Enterococci can also exhibit acquired resistance to high level of aminoglycosides. It is very important to know whether the clinical isolate of Enterococcus is susceptible to high level of aminoglycosides or not. We used disk-diffusion (using high-potency gentamicin and streptomycin) and agarscreening methods to detect HLAR. Agar-screen method was found superior in identifying HLAR. It is possible that disk-diffusion method may not detect borderline resistance. HLAR was significantly higher among E. fecium isolates, an observation which is consistent with that found in previous reports. [16,17] The result of the present study clearly indicates that agar-screen method must be used to confirm HLAR in enterococci. Enterococci are intrinsically resistant to most commonly used antibiotics. Therefore, recommended therapy for serious infections like endocarditis, meningitis or possibly other serious infections in immunodeficient patients includes a cell-wall-active agent such as penicillin or vancomycin, combined with an aminoglycoside like gentamicin or streptomycin. This combination is synergistic in action. [18] However, when an enterococcal strain is resistant to the cell-wall-active agent or has HLAR, there is no synergism and the combination therapy is likely to be unsuccessful. Because of this, it is very important to detect resistance to both the aminoglycosides and the cell-wall-active agents in order to predict the likelihood of synergy. The incidence of infection due to strains of Enterococcus with glycopeptides resistance has increased dramatically. It is also important to know that usually these infections occur in a setting where vancomycin is Burn wound 05 (20) 0 (0) 0 (0) 0 (0) 0 (0) 5 Peritoneal fluid 03 (100) 0 (0) 0 (0) 0 (0) 0 (0) 5   Drug-resistant enterococci present a challenge for the clinician and the clinical microbiologist because of their increased occurrence in nosocomial infections. The situation obligates the clinical microbiologist to try to identify the most useful active antibiotic for treatment. On the other hand, physicians should use antibiotics appropriately and comply with the infection-control policies in an effort to prevent further spread of these resistant organisms.

Strength of the study
• The study identified less common species of Enterococcus -E. casseliflavus, E. durans, E. dispar. • The study also found agar-screen method to be superior in identifying HLAR in enterococci. • The HLAR was found to be significantly higher in E.
fecium by agar-screen method. • The study also detected reduced susceptibility to vancomycin in enterococcal strains.

Limitations of the study
Patients with HLAR and/ or those with reduced susceptibility to vancomycin enterococcal infection could not be followed up, so the outcome of infection with these strains could not be found out.

CONCLUSION
The occurrence of high-level aminoglycoside resistance in enterococcal isolates in our setup was high. Even-though none of the enterococcal strains showed resistance to vancomycin, yet reduced susceptibility to vancomycin was noticed in our study. This would require routine testing of enterococcal isolates for HLAR and vancomycin susceptibility. Agar-screen method was found to be superior to disk-diffusion method in detecting strains resistant to aminoglycosides and vancomycin.

Recommendations on the basis of this study
The study recommends routine testing of enterococcal isolates for HLAR and vancomycin susceptibility. Agarscreen method should be preferred for detection of HLAR in enterococci. MIC for vancomycin should be performed in all laboratories to keep record of increasing resistance of enterococci to vancomycin and for early detection of vancomycin resistance by strain of enterococci.